/PHIO
PHIO Stock - Phio Pharmaceuticals Corp.
Healthcare|BiotechnologyNASDAQ
$1.07+0.94%
+$0.01 (+0.94%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.2
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.18
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PHIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.06 – $1.08
TARGET (TP)$1.23
STOP LOSS$0.98
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.92
52W High$9.79
52W Low$0.97
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-3,643,000 | $-6,332,000 | $-7,012,000 | $-8,886,000 | $-3,716,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-7,387,000 | $-10,824,000 | $-11,462,000 | $-13,511,000 | $-8,793,000 |
| Net Income | $-7,150,000 | $-10,826,000 | $-11,480,000 | $-13,287,000 | $-8,794,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.91 | $-46.87 | $-89.61 | $-111.32 | $-207.25 |
Company Overview
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$14
Average Target
↑ 1208.4% Upside
Now
$14
Low
$14
Average
$14
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 5th 2025 | H.C. Wainwright | Resumed | Buy | $14 |
Earnings History & Surprises
PHIOBeat Rate
71%
Last 14 quarters
Avg Surprise
+4.0%
EPS vs Estimate
Beats / Misses
10/4
Last 12 quarters
Latest EPS
$-0.44
Q4 2025
EPS Surprise History
Q2 24
-17.7%
$-1.53vs$-1.30
Q2 24
No data
Q3 24
+21.1%
$-3.62vs$-4.59
Q4 24
+62.8%
$-1.54vs$-4.14
Q1 25
+30.9%
$-0.85vs$-1.23
Q2 25
No data
Q3 25
-25.0%
$-0.45vs$-0.36
Q4 25
+2.2%
$-0.44vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.45 | $-0.44 | +2.2% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.36 | $-0.45 | -25.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | — | $-0.41 | — | — |
Q1 2025 | Mar 31, 2025 | $-1.23 | $-0.85 | +30.9% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-4.14 | $-1.54 | +62.8% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-4.59 | $-3.62 | +21.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | — | $-4.23 | — | — |
Q2 2024 | Apr 1, 2024 | $-1.30 | $-1.53 | -17.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-12.87 | $-10.26 | +20.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | — | $-13.23 | — | — |
Q2 2023 | May 11, 2023 | — | $-28.35 | — | — |
Q1 2023 | Mar 22, 2023 | $-3.24 | $-2.40 | +25.9% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $38.90 | $-28.09 | -172.2% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-33.50 | $-20.53 | +38.7% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-32.42 | $-20.53 | +36.7% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-34.58 | $-27.01 | +21.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-27.01 | $-30.26 | -12.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-28.09 | $-21.61 | +23.1% | ✓ BEAT |
Q2 2021 | May 13, 2021 | — | $-34.58 | — | — |
Latest News
Phio Pharmaceuticals Completes Enrollment In Phase 1b Trial Of PH-762 siRNA Cancer Therapy
📈 PositiveBenzinga•Nov 25, 2025, 04:33 PM
Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8M Common Shares By The Selling Stockholders
➖ NeutralBenzinga•Nov 20, 2025, 09:10 PM
Phio Pharmaceuticals GAAP EPS of -$0.44 beats by $0.01
➖ NeutralSeeking Alpha•Nov 13, 2025, 09:51 PM
Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:23 PM
Phio Pharmaceuticals' INTASYL PH-762 Wins 2025 Immunomodulatory Solution Of The Year At BioTech Breakthrough Awards
📈 PositiveBenzinga•Nov 7, 2025, 12:46 PM
PHIO stock has given up its prior gain. Phio Pharmaceuticals shares were trading higher after the company announced pathologic results for three patients with cutaneous squamous cell carcinoma who completed treatment in the fifth and final dose cohort of its on-going Phase 1b dose escalation trial.
➖ NeutralBenzinga•Nov 3, 2025, 07:24 PM
Phio Pharma Secures $13.4M Through Warrant Exercises Covering 5.66M Shares, Including Reduced $2.05 Pricing On 4.65M Shares
📈 PositiveBenzinga•Nov 3, 2025, 07:02 PM
Phio Pharmaceuticals shares are trading higher after the company announced pathologic results for three patients with cutaneous squamous cell carcinoma who completed treatment in the fifth and final dose cohort of its on-going Phase 1b dose escalation trial.
📈 PositiveBenzinga•Nov 3, 2025, 02:18 PM
Phio Pharma Reports 100% Tumor Clearance In Final Dose Group Of Skin Cancer Trial
📈 PositiveBenzinga•Nov 3, 2025, 12:49 PM
Phio Pharma To Present Update On Proprietary INTASYL siRNA Technology And Progress On On-Going Clinical Trial With Lead Compound PH-762 For Treatment Of Skin Cancers
📈 PositiveBenzinga•Sep 23, 2025, 11:50 AM
Phio Pharma To Present PH-762 INTASYL siRNA Skin Cancer Trial Progress And Strategic Outlook At Life Sciences Future Conference Sept. 25-26, 2025
📈 PositiveBenzinga•Sep 18, 2025, 11:48 AM
Phio Pharmaceuticals to Discuss Strategy for PH-762 Skin Cancer Drug at Investor Conference
📈 PositiveBenzinga•Sep 3, 2025, 11:51 AM
Phio Pharmaceuticals Has Been Issued Canadian Patent Number 3027780 Titled "REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS"
📈 PositiveBenzinga•Sep 2, 2025, 07:58 PM
Phio Pharmaceuticals stock jumps 24% on partnering with U.S. drug substance manufacturer
📈 PositiveSeeking Alpha•Jul 25, 2025, 12:24 PM
Frequently Asked Questions about PHIO
What is PHIO's current stock price?
Phio Pharmaceuticals Corp. (PHIO) is currently trading at $1.07 per share. The stock has moved +0.94% today.
What is the analyst price target for PHIO?
No analyst price targets are currently available for this stock.
What sector is Phio Pharmaceuticals Corp. in?
Phio Pharmaceuticals Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PHIO's market cap?
Phio Pharmaceuticals Corp. has a market capitalization of $0.01 billion, making it a small-cap company.
Does PHIO pay dividends?
No, Phio Pharmaceuticals Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
GLTO
Galecto, Inc.
$27.17
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
MRKR
Marker Therapeutics, Inc.
$1.28
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.92
Mkt Cap: $0.0B
Explore stocks similar to PHIO for comparison